Pharming Group Stock

Pharming Group EBIT

The EBIT of Pharming Group (PHARM.AS) as of Aug 6, 2026 is 18.30 M USD. In the previous year, EBIT was -2.98 M USD — a change of -713.07% (higher).

EBIT

18.30 MUSD

YoY

-713.07%

Last updated:

In 2026, Pharming Group's EBIT was 18.30 M USD, a -713.07% increase from the -2.98 M USD EBIT recorded in the previous year.

The Pharming Group EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2023
-17.86 base
Jan 1, 2024
-2.98 base
Jan 1, 2025
18.30 base
Jan 1, 2026 (e)
25.54 base
Jan 1, 2027 (e)
28.03 base
Jan 1, 2028 (e)
27.00 base
Jan 1, 2029 (e)
33.57 base
Jan 1, 2030 (e)
56.57 base
YEAREBIT (M USD)
2030 est 56.57
2029 est 33.57
2028 est 27.00
2027 est 28.03
2026 est 25.54
2025 18.30
2024 -2.98
2023 -17.86
2022 15.98
2021 24.40
2020 71.94
2019 59.79
2018 31.96
2017 23.04
2016 -10.85
2015 -12.30
2014 3.07
2013 -8.36
2012 -20.24
2011 -21.01
2010 -51.44
2009 -34.97
2008 -35.95
2007 -31.46
2006 -20.86
Access this data via the Eulerpool API

Pharming Group Revenue

Pharming Group Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
198.86 M USD
-17.86 M USD
-8.55 M USD
Jan 1, 2024
260.34 M USD
-2.98 M USD
-10.38 M USD
Jan 1, 2025
329.63 M USD
18.30 M USD
2.60 M USD
Jan 1, 2026 (e)
407.28 M USD
25.54 M USD
17.11 M USD
Jan 1, 2027 (e)
446.97 M USD
28.03 M USD
24.26 M USD
Jan 1, 2028 (e)
430.48 M USD
27.00 M USD
24.29 M USD
Jan 1, 2029 (e)
535.28 M USD
33.57 M USD
54.64 M USD
Jan 1, 2030 (e)
902.05 M USD
56.57 M USD
80.95 M USD

Pharming Group Margins

Pharming Group stock margins

The Pharming Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pharming Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pharming Group.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
85.23 %
-8.98 %
-4.30 %
Jan 1, 2024
88.13 %
-1.15 %
-3.99 %
Jan 1, 2025
87.90 %
5.55 %
0.79 %
Jan 1, 2026 (e)
87.90 %
6.27 %
4.20 %
Jan 1, 2027 (e)
87.90 %
6.27 %
5.43 %
Jan 1, 2028 (e)
87.90 %
6.27 %
5.64 %
Jan 1, 2029 (e)
87.90 %
6.27 %
10.21 %
Jan 1, 2030 (e)
87.90 %
6.27 %
8.97 %

Pharming Group Stock analysis

What does Pharming Group do? Pharming Group NV was founded in 1988 and is headquartered in the Netherlands. The company specializes in the development and marketing of medical products for the treatment of rare diseases. Its business model is based on the discovery and development of recombinant proteins. These proteins are produced using genetic engineering techniques and serve as the foundation for the development of therapeutic products in various areas. The main focus of Pharming Group NV is the manufacturing and marketing of biopharmaceuticals. The company has a wide range of products used in the treatment of rare diseases, including C1-esterase inhibitor preparations used for acute attacks in hereditary angioedema. Another important product of Pharming Group NV is recombinant human lysozyme. It is used in the treatment of cystic fibrosis and has shown promising results as a therapeutic approach. Pharming Group NV also collaborates closely with various research and development organizations to develop new products and expand knowledge in the medical industry. The company has experienced impressive growth in recent years. In 2019, Pharming Group NV achieved a revenue of 149 million euros. A significant portion of this revenue was generated through the sale of C1-esterase inhibitor preparations. Pharming Group NV has also made a name for itself in the international market. The company has branches in the USA and Europe and works closely with international regulatory authorities to ensure smooth approval and marketing of its products. Overall, Pharming Group NV has a promising future as it continues to invest in research, development, and expansion of its product portfolio. By focusing on the development of products for the treatment of rare diseases, Pharming Group NV positions itself as a leading company in the medical industry and contributes to improving the lives of people worldwide. Pharming Group is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Pharming Group's EBIT

Pharming Group's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Pharming Group's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Pharming Group's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Pharming Group’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Pharming Group stock

EBIT of Pharming Group is 18.30 M USD in 2026.

EBIT of Pharming Group changed from -2.98 M USD to 18.30 M USD, representing a -713.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Pharming Group since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Pharming Group historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Pharming Group

All Key Metrics — Pharming Group